Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-12 02:10 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Different Protocols in Ovarian Stimulation in Intracytoplasmic Sperm Injection Cycles
NCT04193930 · Assiut University · NA · withdrawn · last registry update 2022-11-30 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “no women were recruited” | – | Registry record, Assiut University |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against CYP19A1 within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2023-10-10Phase 3 first posted: Verastem, Inc., avutometinib + Defactinib (NCT06072781)
- 2023-08-31Results posted on the registry: Dana-Farber Cancer Institute, Letrozole + Tamoxifen (NCT02764541)
- 2023-08-30Phase 3 first posted: Olema Pharmaceuticals, Inc., Palazestrant + Fulvestrant (NCT06016738)
- 2023-08-24Phase 3 first posted: Tianjin Medical University Cancer Institute and Hospital, dalpiciclib、Exemestane、Gosserine + Docetaxel for injection、Epirubicin hydrochloride for injection、Cyclophosphamide for injection (NCT06009627)
- 2023-08-21Results posted on the registry: University of Alabama at Birmingham, Letrozole + Everolimus (NCT02520063)
- 2023-07-19Phase 3 first posted: AstraZeneca, Camizestrant + Tamoxifen (NCT05952557)
- 2023-07-06Results posted on the registry: Sanofi, Amcenestrant-matching placebo + SAR439859 (NCT04478266)
- 2023-06-27Results posted on the registry: National Cancer Institute (NCI), Anastrozole + Exemestane (NCT01272037)
- 2023-06-18Phase 3 first posted: Pfizer, Vepdegestrant (ARV-471/PF-07850327) + Palbociclib (NCT05909397)
- 2023-06-08Phase 3 first posted: Hoffmann-La Roche, Inavolisib + Phesgo (NCT05894239)
- 2023-05-16Phase 3 first posted: Shanghai Pharmaceuticals Holding Co., Ltd, SPH4336 Tablets + SPH4336 Tablets Placebo (NCT05860465)
- 2023-04-24Phase 3 first posted: Novartis Pharmaceuticals, Ribociclib + Letrozole (NCT05827081)
- 2023-03-30Results posted on the registry: Sanofi, Amcenestrant + Fulvestrant (NCT04059484)
- 2023-03-22Phase 3 first posted: Chia Tai Tianqing Pharmaceutical Group Co., Ltd., TQB3616 capsules, Letrozole, Anastrozole, Tamoxifen + Placebo capsules, Letrozole, Anastrozole, Tamoxifen (NCT05780567)
- 2023-03-20Phase 3 first posted: AstraZeneca, Camizestrant + Tamoxifen (NCT05774951)
- 2023-02-27Phase 3 first posted: Shanghai Pharmaceuticals Holding Co., Ltd, SPH4336 Tablets 400mg + SPH4336 Tablets Placebo (NCT05744687)
- 2022-12-13Results posted on the registry: M.D. Anderson Cancer Center, Letrozole + RAD001 (Everolimus) (NCT01068249)
- 2022-12-09Phase 3 first posted: Tolmar Inc., TOL2506 + Tamoxifen (NCT05645536)
- 2022-11-01Phase 3 first posted: Ente Ospedaliero Ospedali Galliera, Letrozole tablets + carboplatin AUC 5 and paclitaxel 175 mg/m2 (NCT05601700)
- 2022-10-19Phase 3 first posted: Georgios Papadakis, Anastrozole + Semaglutide (NCT05586802)
- 2022-10-18Results posted on the registry: Medical College of Wisconsin, Anastrozole + Letrozole (NCT03219476)
- 2022-09-29Results posted on the registry: Boehringer Ingelheim, Xentuzumab + Placebo (NCT03659136)
- 2022-08-24Phase 3 first posted: Eli Lilly and Company, Imlunestrant + Tamoxifen (NCT05514054)
- 2022-08-23Phase 3 first posted: European Organisation for Research and Treatment of Cancer - EORTC, Elacestrant + Tamoxifen (NCT05512364)
- 2022-07-12Phase 3 first posted: Fudan University, Letrozole 2.5mg (NCT05454358)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision